Praxis Precision Medicines (NASDAQ:PRAX) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $313.82 and traded as high as $335.18. Praxis Precision Medicines shares last traded at $332.97, with a volume of 1,120,108 shares trading hands.

Praxis Precision Medicines News Summary

These are some of the PRAX news items that stood out recently:

• Positive Sentiment: BTIG Research assigned the stock a Buy rating. RBC also raised its target to $478 from $462 and maintained an Outperform rating, signaling confidence in potential upside. BTIG Buy rating
• Neutral Sentiment: Praxis presented at the Guggenheim Healthcare Innovation Conference. The available headline does not identify a new announcement or specific update likely to move the shares. Guggenheim conference transcript
• Negative Sentiment: A separate article characterized PRAX as expensive relative to book value, adding to valuation concerns. Praxis stock valuation article

Wall Street Analyst Weigh In

PRAX has been the topic of several analyst reports. Raymond James Financial reissued a “strong-buy” rating and issued a $945.00 price objective on shares of Praxis Precision Medicines in a research note on Monday, August 17th. BTIG Research reaffirmed a “buy” rating and set a $826.00 target price on shares of Praxis Precision Medicines in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Praxis Precision Medicines in a research report on Monday, August 24th. Royal Bank Of Canada lifted their target price on Praxis Precision Medicines from $462.00 to $478.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating on shares of Praxis Precision Medicines in a research report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Praxis Precision Medicines presently has a consensus rating of “Moderate Buy” and a consensus target price of $631.68.

Praxis Precision Medicines Trading Up 2.6%

The stock has a fifty day simple moving average of $291.24 and a two-hundred day simple moving average of $313.99.

Praxis Precision Medicines (NASDAQ:PRAX) last announced its earnings results on Monday, November 9th. The company reported ($3.23) EPS for the quarter, beating the consensus estimate of ($3.54) by $0.31. Sell-side analysts predict that Praxis Precision Medicines, Inc. will post -14.03 earnings per share for the current year.

Hedge Funds Weigh In On Praxis Precision Medicines

Institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC grew its position in shares of Praxis Precision Medicines by 6.8% during the 1st quarter. Janus Henderson Group PLC now owns 3,458,863 shares of the company’s stock worth $1,113,514,000 after buying an additional 218,777 shares during the period. GW&K Investment Management LLC acquired a new position in shares of Praxis Precision Medicines during the 3rd quarter valued at $61,488,000. Bank of New York Mellon Corp acquired a new position in shares of Praxis Precision Medicines during the 2nd quarter valued at $28,583,000. Orbimed Advisors LLC lifted its position in shares of Praxis Precision Medicines by 82.5% during the 1st quarter. Orbimed Advisors LLC now owns 172,500 shares of the company’s stock valued at $55,578,000 after acquiring an additional 78,000 shares during the period. Finally, Aberdeen Group plc boosted its stake in Praxis Precision Medicines by 28.2% during the third quarter. Aberdeen Group plc now owns 213,400 shares of the company’s stock worth $62,148,000 after acquiring an additional 47,001 shares in the last quarter. 67.84% of the stock is currently owned by institutional investors.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.